Addressing Platelet Refractoriness: Giving Hematology-Oncology Patients the Best Chance of Success
The activation of platelets is a well-documented phenomenon. It is now clear that many donated platelet transfusions contain activated platelets. This situation can lead to serious implications for the treatment of hematology-oncology patients who are dependent on platelet transfusion support during their treatment. This webinar will introduce activated platelets and their prevalence, discuss the impacts of activated platelet transfusions, and present a practical solution to this situation.
Speaker: Dr. Elisabeth Maurer-Spurej, PhD, Founder, LightIntegra Technology